Research programme: G protein-coupled receptor modulators - Boehringer Ingelheim/Domain Therapeutics
Alternative Names: GPCR modulators - Boehringer Ingelheim/Domain TherapeuticsLatest Information Update: 28 Jan 2023
At a glance
- Originator Domain Therapeutics
- Developer Boehringer Ingelheim; Domain Therapeutics
- Class Neuropsychotherapeutics; Small molecules
- Mechanism of Action G protein-coupled receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported CNS disorders
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for research development in CNS-disorders in France
- 04 Dec 2018 Boehringer Ingelheim and Domain Therapeutics enter into a collaboration and licensing agreement for development of G protein-coupled receptor modulators for treatment of CNS disorders
- 04 Dec 2018 Early research in CNS disorders in France (unspecified route)